A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury
NCT ID: NCT00036062
Last Updated: 2006-07-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
600 participants
INTERVENTIONAL
2001-08-31
2002-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients entered into this study will be randomly assigned to one of two treatment groups: a sivelestat group or a placebo group. Once entered into the study, patients are monitored for up to 6 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sivelestat
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* be on mechanical ventilation
Exclusion Criteria
* have severe underlying medical problems
* be unlikely to survive
* be pregnant or breast-feeding
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Indianapolis, Indiana, United States
Des Moines, Iowa, United States
Kansas City, Kansas, United States
Lexington, Kentucky, United States
Louisville, Kentucky, United States
Baton Rouge, Louisiana, United States
Lake Charles, Louisiana, United States
Shreveport, Louisiana, United States
Portland, Maine, United States
Baltimore, Maryland, United States
Silver Spring, Maryland, United States
Towson, Maryland, United States
Boston, Massachusetts, United States
Detroit, Michigan, United States
Kalamazoo, Michigan, United States
St Louis, Missouri, United States
Camden, New Jersey, United States
Hackensack, New Jersey, United States
Holmdel, New Jersey, United States
Buffalo, New York, United States
Elmhurst, New York, United States
Manhasset, New York, United States
Mineola, New York, United States
New York, New York, United States
San Diego, California, United States
Denver, Colorado, United States
Englewood, Colorado, United States
New Haven, Connecticut, United States
Washington D.C., District of Columbia, United States
Bay Pines, Florida, United States
Clearwater, Florida, United States
Fort Lauderdale, Florida, United States
Augusta, Georgia, United States
Austell, Georgia, United States
Chicago, Illinois, United States
Elk Grove Village, Illinois, United States
Maywood, Illinois, United States
North Chicago, Illinois, United States
Birmingham, Alabama, United States
Phoenix, Arizona, United States
Tucson, Arizona, United States
Orange, California, United States
Sacramento, California, United States
Rochester, New York, United States
The Bronx, New York, United States
Greensboro, North Carolina, United States
Winston-Salem, North Carolina, United States
Akron, Ohio, United States
Cincinnati, Ohio, United States
Toledo, Ohio, United States
Portland, Oregon, United States
Allentown, Pennsylvania, United States
Hershey, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Providence, Rhode Island, United States
Sioux Falls, South Dakota, United States
Memphis, Tennessee, United States
Nashville, Tennessee, United States
Houston, Texas, United States
Irving, Texas, United States
Lubbock, Texas, United States
San Antonio, Texas, United States
Newport News, Virginia, United States
Morgantown, West Virginia, United States
Garran, Australian Capital Territory, Australia
Camperdown, New South Wales, Australia
Kingswood, New South Wales, Australia
Kogarah, New South Wales, Australia
St Leonards, New South Wales, Australia
Wentworthville, New South Wales, Australia
Southport, Queensland, Australia
Adelaide, South Australia, Australia
Bedford Park, South Australia, Australia
Woodville, South Australia, Australia
Heidelberg, Victoria, Australia
Parkville, Victoria, Australia
Prahran, Victoria, Australia
Fremantle, Western Australia, Australia
Perth, Western Australia, Australia
Aaist, , Belgium
Antwerp, , Belgium
Arion, , Belgium
Braine-l'Alleud, , Belgium
Bruges, , Belgium
Brussels, , Belgium
Ghent, , Belgium
Liège, , Belgium
Edmonton, Alberta, Canada
Vancouver, British Columbia, Canada
Winnipeg, Manitoba, Canada
Halifax, Nova Scotia, Canada
Hamilton, Ontario, Canada
Toronto, Ontario, Canada
Windsor, Ontario, Canada
Montreal, Quebec, Canada
Sherbrooke, Quebec, Canada
Christchurch, Canterbury, New Zealand
Auckland, , New Zealand
Hastings, , New Zealand
Wellington, , New Zealand
Badajoz, Badajoz, Spain
Manresa, Barcelona, Spain
Sabadell, Barcelona, Spain
Getafe, Madrid, Spain
Madrid, Madrid, Spain
El Palmar, Murcia, Spain
Murcia, Murcia, Spain
Palma de Mallorca, Palma de Mallorca, Spain
Barcelona, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H6W-MC-MCAA
Identifier Type: -
Identifier Source: secondary_id
6025
Identifier Type: -
Identifier Source: org_study_id